CD22: CD22 molecule
1 protein, 153 patents, 13 drugs, 116 trials, 3,092 NIH grants and 8,823 papers.
Gene 7
Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.
Proteins 1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in | Source |
|---|---|---|---|---|---|
| P20273 | B-cell receptor CD22 | 847 | 7 | Ensembl, GeneID, HGNC | UniProt |
Patents 153
Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| US 12600781 B2 | 2026-04-14 | 437 | P20273 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 107 | P20273 | Espacenet |
| EP 4641201 A2 | 2025-10-29 | 79 | P20273 | Espacenet |
| JP 2025147176 A | 2025-10-06 | 2269 | P20273 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 790 | P20273 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 5771 | P20273 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 5771 | P20273 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 790 | P20273 | Espacenet |
| US 12331117 B2 | 2025-06-17 | 201 | P20273 | Espacenet |
| JP 2025517969 A | 2025-06-12 | 79 | P20273 | Espacenet |
Drugs 13
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| BECTUMOMAB | CHEMBL2108228 | CD22 other | OTHER | ChEMBL |
| BL22 | CHEMBL2109352 | CD22 binding agent | BINDING AGENT | ChEMBL |
| EPRATUZUMAB | CHEMBL2108404 | CD22 inhibitor | INHIBITOR | ChEMBL |
| EPRATUZUMAB 90Y | CHEMBL2108357 | CD22 binding agent | BINDING AGENT | ChEMBL |
| EPRATUZUMAB-CYS-TESIRINE | CHEMBL4297872 | B-cell receptor CD22 binding agent | BINDING AGENT | ChEMBL |
| IMMURAIT-LL2 | CHEMBL2109508 | CD22 binding agent | BINDING AGENT | ChEMBL |
| INOTUZUMAB | CHEMBL4297558 | CD22 binding agent | BINDING AGENT | ChEMBL |
| INOTUZUMAB OZOGAMICIN | CHEMBL2108611 | CD22 binding agent | BINDING AGENT | ChEMBL |
| MONO-DGA-RFB4 | CHEMBL2109354 | CD22 binding agent | BINDING AGENT | ChEMBL |
| MOXETUMOMAB PASUDOTOX | CHEMBL1743043 | CD22 binding agent | BINDING AGENT | ChEMBL |
Trials 116
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07476729 | INOTUZUMAB OZOGAMICIN | PHASE3 | ClinicalTrials.gov | |
| NCT07443592 | INOTUZUMAB | ClinicalTrials.gov | ||
| NCT07443488 | INOTUZUMAB OZOGAMICIN | PHASE2 | ClinicalTrials.gov | |
| NCT07313852 | INOTUZUMAB | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07238907 | INOTUZUMAB OZOGAMICIN | ClinicalTrials.gov | ||
| NCT06985485 | INOTUZUMAB OZOGAMICIN | PHASE2 | ClinicalTrials.gov | |
| NCT06863259 | INOTUZUMAB OZOGAMICIN | PHASE1 | ClinicalTrials.gov | |
| NCT06861348 | INOTUZUMAB OZOGAMICIN | PHASE2 | ClinicalTrials.gov | |
| NCT06554626 | INOTUZUMAB OZOGAMICIN | PHASE2 | ClinicalTrials.gov | |
| NCT06533748 | INOTUZUMAB | PHASE2 | ClinicalTrials.gov |
NIH grants 3092
NIH projects whose papers are about the gene, through NIH's grant-paper links.
| Project | Title | Its papers about the gene | Newest fiscal year | Source |
|---|---|---|---|---|
| P30CA016672 | Cancer Center Support Grant | 126 | 2,025 | NIH's project files |
| P30CA008748 | Cancer Center Support Grant | 84 | 2,025 | NIH's project files |
| ZIABC010301 | Development of Recombinant Toxins to Treat Hematologic Malignancies | 48 | 2,025 | NIH's project files |
| ZIABC011823 | Development of Novel Approaches to Optimize CAR T-cell Therapies for B-cell Malignancies | 34 | 2,025 | NIH's project files |
| ZICSC009372 | Flow cytometric analysis of benign and malignant tumors | 32 | 2,025 | NIH's project files |
| P30CA021765 | Cancer Center Support Grant (CCSG) | 25 | 2,025 | NIH's project files |
| ZICBC011104 | Flow cytometric evaluation of biomarkers | 25 | 2,025 | NIH's project files |
| ZIABC010891 | Development of antibody engineering-based cancer therapies | 17 | 2,025 | NIH's project files |
| ZIABC008757 | Bio-Therapies for the Treatment of Cancer | 16 | 2,025 | NIH's project files |
| P01CA065493 | Off-the-Shelf Immune Effector Cells for Hematological Malignancies | 13 | 2,025 | NIH's project files |
Papers 8823
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| PMID | Found by | Source |
|---|---|---|
| 42813001 | PubTator, text mining | PubMed |
| 42807925 | PubTator, text mining | PubMed |
| 42802798 | PubTator, text mining | PubMed |
| 42789493 | PubTator, text mining | PubMed |
| 42779306 | PubTator, text mining | PubMed |
| 42765973 | PubTator, text mining | PubMed |
| 42755425 | PubTator, text mining | PubMed |
| 42716964 | PubTator, text mining | PubMed |
| 42702241 | PubTator, text mining | PubMed |
| 42690647 | PubTator, text mining | PubMed |
Release gene-search-2026-11-11-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
HGNC: CC0: https://www.genenames.org/about/license/
NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH's project files and grant-paper links: Public domain (NIH RePORTER)
Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubTator 3: Public domain
UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license